Zhengye Biotechnology Holding Limited Long Term Debt

The latest long-term debt for ZYBT is $9.2M as of December 2025. That compares with $4.8M in the prior-year period — up 91.2% year over year. Investors often review this figure alongside Zhengye Biotechnology Holding Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZYBT's long-term debt moved from $4.8M to $9.2M — a 91.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zhengye Biotechnology Holding Limited's operating scale or balance-sheet position.

A long-term debt figure of $9.2M for ZYBT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ZYBT's long-term debt ($9.2M), review year-over-year change from $4.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.